(A, B) Expression profile (means +/− s.e.m) of AR activated (A) and suppressed (B) genes in WT and Pten-null murine prostates after castration. (C) Heat map of expression ratios of androgen responsive genes in WT (14-day post castration) and intact Pten-null mutants with respect to intact WT mice. (D) Variation in expression of androgen-responsive genes based on PTEN copy number (CN) in human CaP samples. Left, summary of human samples based on PTEN CN (the numbers inside parentheses indicates the number of metastatic cases); right, a comparative analysis of AR activated (red circles) and suppressed (blue circles) gene expression values in two human CaP datasets. (E) Top, gene expression and NCA derived activities of EGR1, JUN, and AR transcription factors in induced PTEN expression in Pten−/− cells. Bottom, the activity of AR in murine models when PTEN/AKT/mTOR pathway was manipulated genetically or pharmacologically. (F) Expression (means +/− SD) of Ezh2 (left), and AR and EZH2 co-target genes (right) in PIN and cancer (CAN) stages of Pten-null prostate. *, p<0.05; **, p<0.005. See also and .